Sysmex (OTCMKTS:SSMXY) Shares Gap Up on Earnings Beat

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped up prior to trading on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $10.94, but opened at $12.1755. Sysmex shares last traded at $12.5150, with a volume of 7,343 shares traded.

The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.The company had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Sysmex presently has an average rating of “Hold”.

Sysmex Stock Up 14.4%

The company has a market cap of $7.88 billion, a P/E ratio of 29.80 and a beta of 1.05. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $9.38 and its 200 day moving average is $9.07.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.